Phase II Trial of Nab-Paclitaxel, Cisplatin, and 5-FU (ACF) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Percentage of Participants With Complete Response (CR) by Clinical Exam at Primary Tumor Site
研究概览
简要总结
This phase II trial studies the safety and effectiveness of an induction chemotherapy (ACF) consisting of paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel), cisplatin and fluorouracil followed by chemoradiation therapy in treating patients with stage III-IV squamous cell cancer of the head and neck. ACF may be an effective way to reduce or downgrade locally aggressive tumors, and improve the chance of eradication by chemoradiation.
详细描述
Compared to the standard induction regimen of TPF (docetaxel, cisplatin, and 5-FU), the ACCF (nab-paclitaxel, cisplatin, cetuximab, and 5-FU) regimen included two therapeutic changes: nab-paclitaxel was substituted for docetaxel and cetuximab was added. The investigators propose to eliminate cetuximab from the ACCF regimen to isolate the treatment effects of nab-paclitaxel when given with cisplatin and 5-FU. The primary objective of the ACF proposal is to determine the complete (CR) rate by clinical examination at the primary tumor site following two cycles of ACF. An important secondary objective will be to compare the tumor response rates at the primary site following two cycles of ACF to our historical experience following two cycles of ACCF (protocol # ABX 218/HRPO# 08-0911). In addition, the investigators will compare adverse events (AEs) between patients who receive ACF to the historical group given ACCF. From these two comparisons, we aim to determine if either ACF or ACCF is superior based on a balance of efficacy (using the surrogate prognostic endpoint of CR rate at primary tumor site) and toxicity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient must have selected stage III or IVa/b head and neck squamous cell carcinoma (HNSCC); all patients must have T2-T4 primary tumors; (patients with T1 tumors will be excluded); although most of these patients will have regional nodal disease, patients with no nodal disease will also be eligible
- •Patient must have disease at the oropharynx, hypopharynx, larynx, or oral cavity sub-sites
- •Patient must have measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 10 mm with CT scan
- •Patient must be >= 18 years of age.
- •Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status =< 2
- •Patient must have adequate bone marrow and organ function as defined below:
- •Absolute neutrophil count (ANC) >= 1500/mcL
- •Platelets > 100,000/mcL
- •Hemoglobin > 9.0 g/dL
- •Total bilirubin =< 1.5 mg/dL
- •Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
- •Alkaline phosphatase =< 2.5 x ULN
- •Serum creatinine < 1.8 mg/dL
- •Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry, for the duration of study participation, and for 3 months after completing treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately
- •Patient must be able to understand and willing to sign an Institutional Review Board (IRB)-approved written informed consent document
- •Patient with uncontrolled diabetes or fasting blood glucose level of greater than 200 mg/dL will be eligible for enrollment but will not be evaluable for PET imaging
排除标准
- •Patient must not have had prior chemotherapy, prior epidermal growth factor receptor (EGFR) targeted therapy, or prior radiation therapy for HNSCC
- •Patient must not have disease at the nasopharyngeal, sinus, or other sub-site not specified in the inclusion criteria; patient must not have unknown primary squamous cell carcinoma of the head and neck
- •Patient must not have a history of prior invasive malignancy diagnosed within 3 years prior to study enrollment other than local stage non-melanoma skin cancer
- •Patient must not be receiving any other investigational agents
- •Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the agents used in this study
- •Patient must not be taking cimetidine or allopurinol. If currently taking either of these medications, patient must discontinue for one week before receiving treatment with nab-paclitaxel
- •Patient must not have an uncontrolled intercurrent illness including, but not limited to, ongoing or active serious infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or serious psychiatric illness/social situations that would limit compliance with study requirements
- •Patient must not be pregnant and/or breastfeeding; a negative serum or urine pregnancy test is required at screening for all female patients of childbearing potential
- •Patient must not be known to be human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with the study agents; in addition, these patients are at increased risk of lethal infections when treated with marrow suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
- •Patient must not have peripheral neuropathy > grade 1
研究组 & 干预措施
Arm 1-ACF Induction Therapy Followed by Chemoradiation Therapy
ACF Induction Therapy (Cycle 1 and Cycle 2 - each cycle is every 3 weeks)
- nab-Paclitaxel 100 mg/m^2 on Days 1, 8, and 15
- Cisplatin 75 mg/m^2 on Day 1
- 5-FU 750 mg/m^2 on Days 1-3
If patient has complete or partial response, he/she will receive an additional ACF cycle (cycle 3). If patient has stable disease or progressive disease will not receive the third cycle of ACF.
Definitive Therapy
- Cisplatin 100 mg/m^2 IV on Days 1, 22, and 43
- Intensity modulated radiation therapy (IMRT) 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to area considered to be at intermediate risk. Additional regions in the ipsilateral and contralateral neck at risk for microscopic disease in the cervical lymph nodes will receive 5600 cGy in 35 fractions.
- If patient cannot receive cisplatin then he/she will receive cetuximab 250 mg/m^2 IV week for 8 weeks
干预措施: paclitaxel albumin-stabilized nanoparticle formulation (Drug)
Arm 1-ACF Induction Therapy Followed by Chemoradiation Therapy
ACF Induction Therapy (Cycle 1 and Cycle 2 - each cycle is every 3 weeks)
- nab-Paclitaxel 100 mg/m^2 on Days 1, 8, and 15
- Cisplatin 75 mg/m^2 on Day 1
- 5-FU 750 mg/m^2 on Days 1-3
If patient has complete or partial response, he/she will receive an additional ACF cycle (cycle 3). If patient has stable disease or progressive disease will not receive the third cycle of ACF.
Definitive Therapy
- Cisplatin 100 mg/m^2 IV on Days 1, 22, and 43
- Intensity modulated radiation therapy (IMRT) 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to area considered to be at intermediate risk. Additional regions in the ipsilateral and contralateral neck at risk for microscopic disease in the cervical lymph nodes will receive 5600 cGy in 35 fractions.
- If patient cannot receive cisplatin then he/she will receive cetuximab 250 mg/m^2 IV week for 8 weeks
干预措施: Cisplatin (Drug)
Arm 1-ACF Induction Therapy Followed by Chemoradiation Therapy
ACF Induction Therapy (Cycle 1 and Cycle 2 - each cycle is every 3 weeks)
- nab-Paclitaxel 100 mg/m^2 on Days 1, 8, and 15
- Cisplatin 75 mg/m^2 on Day 1
- 5-FU 750 mg/m^2 on Days 1-3
If patient has complete or partial response, he/she will receive an additional ACF cycle (cycle 3). If patient has stable disease or progressive disease will not receive the third cycle of ACF.
Definitive Therapy
- Cisplatin 100 mg/m^2 IV on Days 1, 22, and 43
- Intensity modulated radiation therapy (IMRT) 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to area considered to be at intermediate risk. Additional regions in the ipsilateral and contralateral neck at risk for microscopic disease in the cervical lymph nodes will receive 5600 cGy in 35 fractions.
- If patient cannot receive cisplatin then he/she will receive cetuximab 250 mg/m^2 IV week for 8 weeks
干预措施: Fluorouracil (Drug)
Arm 1-ACF Induction Therapy Followed by Chemoradiation Therapy
ACF Induction Therapy (Cycle 1 and Cycle 2 - each cycle is every 3 weeks)
- nab-Paclitaxel 100 mg/m^2 on Days 1, 8, and 15
- Cisplatin 75 mg/m^2 on Day 1
- 5-FU 750 mg/m^2 on Days 1-3
If patient has complete or partial response, he/she will receive an additional ACF cycle (cycle 3). If patient has stable disease or progressive disease will not receive the third cycle of ACF.
Definitive Therapy
- Cisplatin 100 mg/m^2 IV on Days 1, 22, and 43
- Intensity modulated radiation therapy (IMRT) 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to area considered to be at intermediate risk. Additional regions in the ipsilateral and contralateral neck at risk for microscopic disease in the cervical lymph nodes will receive 5600 cGy in 35 fractions.
- If patient cannot receive cisplatin then he/she will receive cetuximab 250 mg/m^2 IV week for 8 weeks
干预措施: Intensity modulated radiation therapy (Radiation)
Arm 1-ACF Induction Therapy Followed by Chemoradiation Therapy
ACF Induction Therapy (Cycle 1 and Cycle 2 - each cycle is every 3 weeks)
- nab-Paclitaxel 100 mg/m^2 on Days 1, 8, and 15
- Cisplatin 75 mg/m^2 on Day 1
- 5-FU 750 mg/m^2 on Days 1-3
If patient has complete or partial response, he/she will receive an additional ACF cycle (cycle 3). If patient has stable disease or progressive disease will not receive the third cycle of ACF.
Definitive Therapy
- Cisplatin 100 mg/m^2 IV on Days 1, 22, and 43
- Intensity modulated radiation therapy (IMRT) 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to area considered to be at intermediate risk. Additional regions in the ipsilateral and contralateral neck at risk for microscopic disease in the cervical lymph nodes will receive 5600 cGy in 35 fractions.
- If patient cannot receive cisplatin then he/she will receive cetuximab 250 mg/m^2 IV week for 8 weeks
干预措施: Cetuximab (Drug)
Arm 1-ACF Induction Therapy Followed by Chemoradiation Therapy
ACF Induction Therapy (Cycle 1 and Cycle 2 - each cycle is every 3 weeks)
- nab-Paclitaxel 100 mg/m^2 on Days 1, 8, and 15
- Cisplatin 75 mg/m^2 on Day 1
- 5-FU 750 mg/m^2 on Days 1-3
If patient has complete or partial response, he/she will receive an additional ACF cycle (cycle 3). If patient has stable disease or progressive disease will not receive the third cycle of ACF.
Definitive Therapy
- Cisplatin 100 mg/m^2 IV on Days 1, 22, and 43
- Intensity modulated radiation therapy (IMRT) 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to area considered to be at intermediate risk. Additional regions in the ipsilateral and contralateral neck at risk for microscopic disease in the cervical lymph nodes will receive 5600 cGy in 35 fractions.
- If patient cannot receive cisplatin then he/she will receive cetuximab 250 mg/m^2 IV week for 8 weeks
干预措施: Quality-of-life assessment (Procedure)
结局指标
主要结局
Percentage of Participants With Complete Response (CR) by Clinical Exam at Primary Tumor Site
时间窗: 6 weeks (2 cycles of therapy)
* Response will be assessed by laryngoscopy. * CR: disappearance of all lesions
次要结局
- Percentage of Participants With Partial Response (PR) at Primary Tumor Site(6 weeks (2 cycles of therapy))
- Number of Participants Per Anatomic Tumor Response by CT Scan(6 weeks (2 cycles of therapy))
- Metabolic Tumor Responses as Measured by FDG-PET/CT(6 weeks (2 cycles of therapy))
- Overall Survival Rate(2 years)
- Changes in Secreted Protein Acidic and Rich in Cysteine (SPARC) Expression by Immunohistochemistry (IHC) in Primary Tumor Tissue(6 weeks (2 cycles of therapy))
- Complete Response (CR) or Partial Response (PR) at Regional (Neck) Nodes as Measured by Clinical Exam(6 weeks (2 cycles of therapy))
- Changes in Ki-67 Expression by Immunohistochemistry (IHC) in Primary Tumor Tissue(6 weeks (2 cycles of therapy))
- Disease-free Survival (DFS) Rate(2 years)
- Progression-free Survival (PFS)(2 years)
- Quality of Life (QOL) as Measured by Functional Assessment of Cancer Therapy - Head and Neck (FACT-H&N) Total Score(Through one year after completion of treatment)
- Quality of Life (QOL) as Measured by Functional Assessment of Cancer Therapy - Head and Neck (FACT-H&N) FACT-G Total Score(Through end of chemoradiation)
- Quality of Life (QOL) as Measured by Functional Assessment of Cancer Therapy - Head and Neck (FACT-H&N) Trial Outcome Index (TOI)(Through end of chemoradiation)
- Adverse Events as Measured by Number of Participants That Experienced Each Common Adverse Event During ACF Induction Therapy(From start of treatment through 30 days after end of treatment)